Compare PFX & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFX | RPID |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.7M | 84.8M |
| IPO Year | 2010 | 2021 |
| Metric | PFX | RPID |
|---|---|---|
| Price | $44.59 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 1.1K | ★ 314.2K |
| Earning Date | 08-05-2026 | 11-06-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | ★ $33,587,000.00 |
| Revenue This Year | N/A | $16.95 |
| Revenue Next Year | N/A | $17.92 |
| P/E Ratio | $148.63 | ★ N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $38.30 | $0.83 |
| 52 Week High | $56.48 | $4.94 |
| Indicator | PFX | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 21.87 |
| Support Level | $44.01 | N/A |
| Resistance Level | $45.03 | $2.18 |
| Average True Range (ATR) | 0.74 | 0.09 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 17.36 | 8.40 |
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.